Background: Respiratory syncytial virus (RSV) disease places a substantial burden on primary care. Maternal RSV vaccination reduces severe RSV disease and hospitalisation among infants; however, its effects on primary care, where most RSV infections are managed, remain poorly understood. We investigated the effect of maternal RSV vaccination on RSV-related primary care attendance.
Methods: This systematic review and meta-analysis was prospectively registered with PROSPERO (CRD420251169070). MEDLINE, Embase, MIDIRS, CINAHL, Cochrane CENTRAL and Scopus were searched for studies published between January 2000 and January 2026. Eligible studies included pregnant women receiving an RSV vaccine, infants born to vaccinated mothers, a placebo or unvaccinated comparator, and RSV-related infant outcomes including medically attended illness and/or hospitalisation. Random-effects meta-analyses were undertaken. As no studies specifically reported primary care attendance, medically attended RSV lower respiratory tract infection (RSV-LRTI) was used as a proxy.
Results: Four randomised controlled trials involving 17,289 infants born to mothers receiving RSV vaccination or placebo met inclusion criteria. Maternal vaccination reduced medically attended RSV-LRTI at 90 days (OR 0.51, 95% CI 0.38–0.69; p<0.001), with protection persisting to 180 days (OR 0.53, 95% CI 0.35–0.80; p<0.003). RSV-LRTI hospitalisation was also reduced (OR 0.56, 95% CI 0.42–0.76; p<0.001). Two studies had low risk of bias and two had some concerns.
Conclusions: Maternal RSV vaccination reduces medically attended RSV-LRTI and hospitalisation during the first six months of life, potentially reducing primary care burden. Real-world studies are needed to confirm its impact on primary care attendance.
Key messages:
· Maternal RSV vaccination reduces severe RSV disease and hospitalisation in infants, but its impact in primary care, where much RSV illness is managed, is poorly understood.
· Maternal RSV vaccination reduces medically attended RSV-LRTI at 90 and 180 days; however, no studies reported primary care attendance specifically, requiring medically attended RSV-LRTI to be used as a proxy.
· The lack of primary care-specific evidence highlights the need for real-world studies assessing the impact of maternal RSV vaccination on primary care consultations and referrals to secondary care.

